CY1121085T1 - Αντισωματα για θεραπευτικη αγωγη καρκινου που εκφραζει κλαυδινη 6 - Google Patents
Αντισωματα για θεραπευτικη αγωγη καρκινου που εκφραζει κλαυδινη 6Info
- Publication number
- CY1121085T1 CY1121085T1 CY181101393T CY181101393T CY1121085T1 CY 1121085 T1 CY1121085 T1 CY 1121085T1 CY 181101393 T CY181101393 T CY 181101393T CY 181101393 T CY181101393 T CY 181101393T CY 1121085 T1 CY1121085 T1 CY 1121085T1
- Authority
- CY
- Cyprus
- Prior art keywords
- cancer
- treatment
- breast
- claudine
- antibodies
- Prior art date
Links
- 238000011282 treatment Methods 0.000 title abstract 2
- 206010028980 Neoplasm Diseases 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 206010006187 Breast cancer Diseases 0.000 abstract 4
- 208000026310 Breast neoplasm Diseases 0.000 abstract 4
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 206010005003 Bladder cancer Diseases 0.000 abstract 1
- 201000009030 Carcinoma Diseases 0.000 abstract 1
- 206010008342 Cervix carcinoma Diseases 0.000 abstract 1
- 102100038449 Claudin-6 Human genes 0.000 abstract 1
- 206010009944 Colon cancer Diseases 0.000 abstract 1
- 208000022072 Gallbladder Neoplasms Diseases 0.000 abstract 1
- 101000882898 Homo sapiens Claudin-6 Proteins 0.000 abstract 1
- 208000008839 Kidney Neoplasms Diseases 0.000 abstract 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 abstract 1
- 206010033128 Ovarian cancer Diseases 0.000 abstract 1
- 206010061535 Ovarian neoplasm Diseases 0.000 abstract 1
- 206010038389 Renal cancer Diseases 0.000 abstract 1
- 206010039491 Sarcoma Diseases 0.000 abstract 1
- 208000005718 Stomach Neoplasms Diseases 0.000 abstract 1
- 208000024313 Testicular Neoplasms Diseases 0.000 abstract 1
- 206010057644 Testis cancer Diseases 0.000 abstract 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 abstract 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 abstract 1
- 208000002495 Uterine Neoplasms Diseases 0.000 abstract 1
- 201000010881 cervical cancer Diseases 0.000 abstract 1
- 208000029742 colonic neoplasm Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 201000010175 gallbladder cancer Diseases 0.000 abstract 1
- 206010017758 gastric cancer Diseases 0.000 abstract 1
- 201000010536 head and neck cancer Diseases 0.000 abstract 1
- 208000014829 head and neck neoplasm Diseases 0.000 abstract 1
- 201000010982 kidney cancer Diseases 0.000 abstract 1
- 201000005202 lung cancer Diseases 0.000 abstract 1
- 208000020816 lung neoplasm Diseases 0.000 abstract 1
- 230000000771 oncological effect Effects 0.000 abstract 1
- 230000003169 placental effect Effects 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 201000011549 stomach cancer Diseases 0.000 abstract 1
- 201000003120 testicular cancer Diseases 0.000 abstract 1
- 201000005112 urinary bladder cancer Diseases 0.000 abstract 1
- 206010046766 uterine cancer Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Cell Biology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Η παρούσα εφεύρεση παρέχει αντισώματα χρήσιμα ως θεραπευτικά για θεραπευτική και/ή προληπτική αγωγή ασθενειών σχετιζόμενων με κύτταρα που εκφράζουν CLDN6, που περιλαμβάνουν ογκοσχετιζόμενες ασθένειες όπως ωοθηκικό καρκίνο, καρκίνο πνεύμονα, γαστρικό καρκίνο, καρκίνο μαστού, ηπατικό καρκίνο παγκρεατικό καρκίνο, καρκίνο δέρματος, κακόηθες μελάνωμα, καρκίνο κεφαλής και αυχένα, σάρκωμα, καρκίνο χοληφόρων πόρων, καρκίνο ουροδόχου κύστης, νεφρικό καρκίνο, καρκίνο κόλου, πλακούντιο χόριο καρκίνωμα, καρκίνο τραχήλου μήτρας, καρκίνο όρχεων, και καρκίνο μήτρας.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161486071P | 2011-05-13 | 2011-05-13 | |
EP11004004 | 2011-05-13 | ||
EP12715856.6A EP2707390B1 (en) | 2011-05-13 | 2012-04-20 | Antibodies for treatment of cancer expressing claudin 6 |
PCT/EP2012/001721 WO2012156018A1 (en) | 2011-05-13 | 2012-04-20 | Antibodies for treatment of cancer expressing claudin 6 |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1121085T1 true CY1121085T1 (el) | 2019-12-11 |
Family
ID=47176322
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20161100181T CY1118608T1 (el) | 2011-05-13 | 2016-03-01 | Αντισωματα για θεραπευτικη αγωγη καρκινου που εκφραζει κλαυδινη 6 |
CY181101393T CY1121085T1 (el) | 2011-05-13 | 2018-12-21 | Αντισωματα για θεραπευτικη αγωγη καρκινου που εκφραζει κλαυδινη 6 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20161100181T CY1118608T1 (el) | 2011-05-13 | 2016-03-01 | Αντισωματα για θεραπευτικη αγωγη καρκινου που εκφραζει κλαυδινη 6 |
Country Status (29)
Country | Link |
---|---|
US (5) | US9321842B2 (el) |
EP (3) | EP3421496A1 (el) |
JP (3) | JP6276176B2 (el) |
KR (3) | KR102072183B1 (el) |
CN (3) | CN107011440B (el) |
AR (2) | AR086306A1 (el) |
AU (4) | AU2012258087B2 (el) |
BR (1) | BR112013029212B1 (el) |
CA (1) | CA2832174C (el) |
CY (2) | CY1118608T1 (el) |
DK (2) | DK3026064T3 (el) |
ES (1) | ES2565063T3 (el) |
HK (1) | HK1195320A1 (el) |
HR (2) | HRP20160212T1 (el) |
HU (1) | HUE028603T2 (el) |
IL (1) | IL228738B (el) |
LT (1) | LT3026064T (el) |
ME (1) | ME02369B (el) |
MX (4) | MX341147B (el) |
NZ (3) | NZ741567A (el) |
PL (2) | PL3026064T3 (el) |
RS (2) | RS54627B1 (el) |
RU (1) | RU2676731C2 (el) |
SG (1) | SG193551A1 (el) |
SI (2) | SI2707390T1 (el) |
SM (1) | SMT201600064B (el) |
UA (2) | UA115969C2 (el) |
WO (1) | WO2012156018A1 (el) |
ZA (1) | ZA201307102B (el) |
Families Citing this family (43)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP6109475B2 (ja) | 2008-11-28 | 2017-04-05 | テラヴィア ホールディングス, インコーポレイテッド | 従属栄養微生物における、用途に応じた油の生産 |
KR20110128316A (ko) | 2009-02-20 | 2011-11-29 | 가니메드 파마슈티칼스 아게 | 암의 진단 및 치료를 위한 방법 및 조성물 |
US9487584B2 (en) | 2009-11-11 | 2016-11-08 | Ganymed Pharmaceuticals Ag | Antibodies specific for claudin 6 (CLDN6) |
EP2404936A1 (en) | 2010-07-06 | 2012-01-11 | Ganymed Pharmaceuticals AG | Cancer therapy using CLDN6 target-directed antibodies in vivo |
GB201103955D0 (en) * | 2011-03-09 | 2011-04-20 | Antitope Ltd | Antibodies |
EP3421496A1 (en) | 2011-05-13 | 2019-01-02 | Ganymed Pharmaceuticals GmbH | Antibodies for treatment of cancer expressing claudin 6 |
EP2888283B1 (en) | 2012-08-24 | 2018-09-19 | The Regents of The University of California | Antibodies and vaccines for use in treating ror1 cancers and inhibiting metastasis |
WO2015014376A1 (en) * | 2013-07-31 | 2015-02-05 | Biontech Ag | Diagnosis and therapy of cancer involving cancer stem cells |
JP6515111B2 (ja) | 2013-11-06 | 2019-05-22 | アッヴィ・ステムセントルクス・エル・エル・シー | 新規の抗クローディン抗体および使用方法 |
CA2929044A1 (en) | 2013-11-11 | 2015-05-14 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule containing modified antibody variable region |
WO2015108203A1 (ja) * | 2014-01-15 | 2015-07-23 | 株式会社オーダーメードメディカルリサーチ | 抗slc6a6抗体を用いたがん治療用医薬組成物 |
RS58627B2 (sr) * | 2014-04-01 | 2022-06-30 | Biontech Cell&Gene Therapies Gmbh | Klaudin-6-specifični imuno receptori i t-ćelijski epitopi |
TW202313697A (zh) | 2014-11-11 | 2023-04-01 | 日商中外製藥股份有限公司 | 包含經改變之抗體可變區之抗原結合分子的資料庫 |
MX2017005163A (es) | 2014-11-17 | 2018-01-18 | Arno Therapeutics Inc | Composiciones de liberación prolongada de onapristona y métodos. |
CN106146666B (zh) * | 2015-03-26 | 2019-09-06 | 科济生物医药(上海)有限公司 | 靶向cldn6的免疫效应细胞及其制备方法和应用 |
CN105504051B (zh) * | 2015-12-17 | 2019-08-30 | 北京天成新脉生物技术有限公司 | 狂犬病毒核蛋白单克隆抗体及其应用 |
US10688181B2 (en) | 2016-06-27 | 2020-06-23 | The Regents Of The University Of California | Cancer treatment combinations |
US20180148471A1 (en) | 2016-11-30 | 2018-05-31 | Arno Therapeutics, Inc. | Methods for onapristone synthesis dehydration and deprotection |
EP3562844A1 (en) * | 2016-12-28 | 2019-11-06 | Genentech, Inc. | Treatment of advanced her2 expressing cancer |
WO2019048040A1 (en) * | 2017-09-06 | 2019-03-14 | Ganymed Pharmaceuticals Gmbh | ANTIBODIES USEFUL IN THE DIAGNOSIS OF CANCER |
GB202103867D0 (en) * | 2017-09-18 | 2021-05-05 | Univ California | Claudin6 antibodies and methods of treating cancer |
TWI820044B (zh) | 2017-09-29 | 2023-11-01 | 日商第一三共股份有限公司 | 抗體-吡咯并苯二氮呯衍生物複合體 |
EP3720963A4 (en) | 2017-12-05 | 2021-12-08 | Chugai Seiyaku Kabushiki Kaisha | ANTIGEN BINDING MOLECULE INCLUDING A VARIABLE REGION OF MODIFIED ANTIBODIES BINDING TO CD3 AND CD137 |
EP3735463A4 (en) * | 2018-01-05 | 2022-03-02 | Chugai Seiyaku Kabushiki Kaisha | THERAPEUTIC AGENT INDUCING CYTOTOXICITY |
KR102340989B1 (ko) * | 2018-03-28 | 2021-12-20 | 에이비온 주식회사 | 클라우딘 3의 ecl-2에 특이적으로 결합하는 항체, 이의 단편 및 이들의 용도 |
SG11202108281UA (en) | 2019-02-15 | 2021-08-30 | Integral Molecular Inc | Claudin 6 antibodies and uses thereof |
US11254736B2 (en) | 2019-02-15 | 2022-02-22 | Integral Molecular, Inc. | Antibodies comprising a common light chain and uses thereof |
WO2020191344A1 (en) | 2019-03-20 | 2020-09-24 | The Regents Of The University Of California | Claudin-6 bispecific antibodies |
CA3134055A1 (en) * | 2019-03-20 | 2020-09-24 | The Regents Of The University Of California | Claudin-6 antibodies and drug conjugates |
TW202116805A (zh) | 2019-07-10 | 2021-05-01 | 日商中外製藥股份有限公司 | Claudin-6結合分子以及其用途 |
WO2021129927A1 (en) | 2019-12-23 | 2021-07-01 | Biontech Cell & Gene Therapies Gmbh | Treatment with immune effector cells engineered to express an antigen receptor |
CN111087465B (zh) * | 2019-12-24 | 2020-12-08 | 广州医科大学 | 一种针对密蛋白6的抗体偶联药物及应用 |
MX2022012092A (es) | 2020-03-31 | 2022-10-13 | Chugai Pharmaceutical Co Ltd | Moleculas de union al antigeno multiespecificas dirigidas a claudina-6 y sus usos. |
AU2021374036A1 (en) * | 2020-11-06 | 2023-06-08 | Amgen Inc. | Polypeptide constructs selectively binding to cldn6 and cd3 |
CN117157319A (zh) | 2021-03-09 | 2023-12-01 | Xencor股份有限公司 | 结合cd3和cldn6的异二聚抗体 |
US20230008868A1 (en) * | 2021-07-08 | 2023-01-12 | Nippon Telegraph And Telephone Corporation | User authentication device, user authentication method, and user authentication computer program |
JPWO2023053282A1 (el) | 2021-09-29 | 2023-04-06 | ||
CA3234897A1 (en) * | 2021-10-14 | 2023-04-20 | Kunle Odunsi | Compositions and methods for use of recombinant t cell receptors against claudin 6 |
WO2023105005A1 (en) | 2021-12-09 | 2023-06-15 | BioNTech SE | Chimeric antigen receptor-modified cells for the treatment of cldn6 expressing cancer |
WO2024046572A1 (en) | 2022-09-01 | 2024-03-07 | BioNTech SE | Chimeric antigen receptor-modified cells for the treatment of cldn6 expressing cancer |
WO2024088325A1 (zh) * | 2022-10-25 | 2024-05-02 | 科济生物医药(上海)有限公司 | 抗体及其应用 |
WO2024095964A1 (ja) * | 2022-10-31 | 2024-05-10 | アステラス製薬株式会社 | Toll様受容体7/8デュアルアゴニスト化合物を含む抗体薬物複合体 |
CN116064622B (zh) * | 2023-02-13 | 2023-10-13 | 优睿赛思(武汉)生物科技有限公司 | Claudin6-mCherry报告基因CHO-K1稳转细胞株制备及应用 |
Family Cites Families (72)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4946788A (en) | 1985-06-11 | 1990-08-07 | Ciba-Geigy Corporation | Purified immunoglobulin-related factor, novel monoclonal antibodies, hybridoma cell lines, processes and applications |
GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
EP0307434B2 (en) | 1987-03-18 | 1998-07-29 | Scotgen Biopharmaceuticals, Inc. | Altered antibodies |
GB8717430D0 (en) | 1987-07-23 | 1987-08-26 | Celltech Ltd | Recombinant dna product |
GB8809129D0 (en) | 1988-04-18 | 1988-05-18 | Celltech Ltd | Recombinant dna methods vectors and host cells |
US6255458B1 (en) | 1990-08-29 | 2001-07-03 | Genpharm International | High affinity human antibodies and human antibodies against digoxin |
GB9019812D0 (en) | 1990-09-11 | 1990-10-24 | Scotgen Ltd | Novel antibodies for treatment and prevention of infection in animals and man |
US5830755A (en) | 1995-03-27 | 1998-11-03 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | T-cell receptors and their use in therapeutic and diagnostic methods |
US6121022A (en) | 1995-04-14 | 2000-09-19 | Genentech, Inc. | Altered polypeptides with increased half-life |
US5677139A (en) | 1995-04-21 | 1997-10-14 | President And Fellows Of Harvard College | In vitro differentiation of CD34+ progenitor cells into T lymphocytes |
UA56132C2 (uk) | 1995-04-25 | 2003-05-15 | Смітклайн Бічем Байолоджікалс С.А. | Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини |
US6277375B1 (en) | 1997-03-03 | 2001-08-21 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
WO2000078961A1 (en) | 1999-06-23 | 2000-12-28 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
WO2000012708A2 (en) | 1998-09-01 | 2000-03-09 | Genentech, Inc. | Further pro polypeptides and sequences thereof |
US5928631A (en) | 1997-06-09 | 1999-07-27 | The Procter & Gamble Company | Methods for controlling environmental odors on the body using compositions comprising uncomplexed cyclodextrins |
US20020127584A1 (en) | 1997-09-18 | 2002-09-12 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
US5932445A (en) | 1997-11-07 | 1999-08-03 | Incyte Pharmaceuticals, Inc. | Signal peptide-containing proteins |
US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
JP2003524384A (ja) * | 1998-11-03 | 2003-08-19 | アドヘレックス テクノロジーズ インコーポレイテッド | クラウディン媒介機能を調節するための化合物および方法 |
AU3124000A (en) | 1998-12-17 | 2000-07-03 | Human Genome Sciences, Inc. | 47 human secreted proteins |
CA2361743A1 (en) | 1999-02-22 | 2000-08-31 | Michael G. Walker | Genes associated with diseases of the colon |
EP1185648B1 (en) | 1999-06-02 | 2007-03-21 | Genentech, Inc. | Methods and compositions for inhibiting neoplastic cell growth |
EP1067182A3 (en) | 1999-07-08 | 2001-11-21 | Helix Research Institute | Secretory protein or membrane protein |
WO2001053312A1 (en) | 1999-12-23 | 2001-07-26 | Hyseq, Inc. | Novel nucleic acids and polypeptides |
WO2001051513A2 (en) | 2000-01-14 | 2001-07-19 | Corixa Corporation | Ovarian tumor-associated sequences |
AU2001249622B2 (en) | 2000-03-30 | 2007-06-07 | Massachusetts Institute Of Technology | RNA sequence-specific mediators of RNA interference |
AU6531101A (en) | 2000-06-02 | 2001-12-17 | Genentech Inc | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
CA2412211A1 (en) | 2000-06-23 | 2002-01-03 | Genetech, Inc. | Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis |
JP2004516013A (ja) | 2000-07-20 | 2004-06-03 | ジェネンテック・インコーポレーテッド | 血管形成に関連する障害を診断及び治療するための組成物と方法 |
CA2416456A1 (en) | 2000-07-20 | 2002-01-31 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
NZ524523A (en) | 2000-08-03 | 2006-02-24 | Therapeutic Human Polyclonals | Production of humanized antibodies in transgenic animals |
ES2405944T3 (es) | 2000-11-30 | 2013-06-04 | Medarex, Inc. | Ácidos nucleicos que codifican las secuencias de inmunoglobulina humana reorganizadas a partir de ratones transcromoscómicos transgénicos zadas |
US20030133939A1 (en) | 2001-01-17 | 2003-07-17 | Genecraft, Inc. | Binding domain-immunoglobulin fusion proteins |
US7754208B2 (en) | 2001-01-17 | 2010-07-13 | Trubion Pharmaceuticals, Inc. | Binding domain-immunoglobulin fusion proteins |
EP2000545B1 (en) | 2001-06-20 | 2011-08-31 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of lung tumor |
CA2379661A1 (en) | 2002-03-28 | 2003-09-28 | Kursad Turksen | Paracellular drug delivery system |
MXPA04010092A (es) | 2002-04-16 | 2004-12-13 | Genentech Inc | Composiciones y metodos para el diagnostico y tratamiento de tumores. |
WO2003089451A2 (en) * | 2002-04-22 | 2003-10-30 | Dyax Corporation | Antibodies specific for mucin polypeptide |
US20070207142A1 (en) | 2002-05-08 | 2007-09-06 | Genentech, Inc. | Compositions and methods for the treatment of tumor of hematopoietic origin |
JP2006516089A (ja) | 2002-10-02 | 2006-06-22 | ジェネンテック・インコーポレーテッド | 腫瘍の診断と治療のための組成物と方法 |
WO2004035607A2 (en) | 2002-10-17 | 2004-04-29 | Genmab A/S | Human monoclonal antibodies against cd20 |
WO2004060270A2 (en) | 2002-10-18 | 2004-07-22 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of tumor |
AT500651B9 (de) | 2003-05-27 | 2010-04-15 | Altropus Gmbh | Aktiv immunisierender antikörper |
KR20060035608A (ko) | 2003-05-30 | 2006-04-26 | 센토코 인코포레이티드 | 항 조직 인자 항체로 종양 성장을 저해하는 방법 |
AU2004256425A1 (en) | 2003-06-09 | 2005-01-20 | The Regents Of The University Of Michigan | Compositions and methods for treating and diagnosing cancer |
US20080305493A1 (en) | 2004-03-08 | 2008-12-11 | Avalon Pharmaceuticals | Determining Cancer-Linked Genes and Therapeutic Targets Using Molecular Cytogenetic Methods |
US7431927B2 (en) | 2005-03-24 | 2008-10-07 | Epitomics, Inc. | TNFα-neutralizing antibodies |
DE102005025041A1 (de) | 2005-05-30 | 2006-12-07 | Bell Flavors & Fragrances Duft Und Aroma Gmbh | Mittel zur Anwendung in Spülmaschinen sowie Vorrichtung für dessen dosierte Einbringung während der Spül- und Trocknungsphasen |
EP1790664A1 (en) * | 2005-11-24 | 2007-05-30 | Ganymed Pharmaceuticals AG | Monoclonal antibodies against claudin-18 for treatment of cancer |
EP1970384A1 (en) * | 2007-03-14 | 2008-09-17 | Ganymed Pharmaceuticals AG | Monoclonal antibodies for treatment of cancer |
WO2008114733A1 (ja) | 2007-03-16 | 2008-09-25 | Kyowa Hakko Kirin Co., Ltd. | 抗Claudin-4抗体 |
EP1997832A1 (en) | 2007-05-29 | 2008-12-03 | Ganymed Pharmaceuticals AG | Monoclonal antibodies against Claudin-18 for treatment of cancer |
WO2009025759A1 (en) * | 2007-08-17 | 2009-02-26 | Progenics Pharmaceuticals (Nevada), Inc. | Tight junction proteins associated with infection and entry of hepatitis c virus (hcv), methods and uses thereof |
WO2009028663A1 (ja) * | 2007-08-30 | 2009-03-05 | Kyowa Hakko Kirin Co., Ltd. | 抗Claudin-3抗体 |
EP2060583A1 (en) | 2007-10-23 | 2009-05-20 | Ganymed Pharmaceuticals AG | Identification of tumor-associated markers for diagnosis and therapy |
US9274119B2 (en) * | 2008-01-11 | 2016-03-01 | The University Of Tokyo | Anti-CLDN6 antibody |
EP2285392A4 (en) | 2008-04-11 | 2012-06-06 | Bionovo Inc | PROCEDURE AGAINST CANCER WITH EXTRACTS FROM GLEDITSIA SINENSIS LAM |
WO2010043650A2 (en) | 2008-10-14 | 2010-04-22 | Ablynx Nv | Amino acid sequences directed against cellular receptors for viruses and bacteria |
DE102009026966A1 (de) | 2008-12-18 | 2010-07-01 | Robert Bosch Gmbh | Betrieb eines Bremskraftverstärkers als Pedalsimulator |
JP2010178650A (ja) | 2009-02-04 | 2010-08-19 | Univ Of Tokyo | 固形癌の再発予測のための試験方法および再発予防剤 |
KR20110128316A (ko) | 2009-02-20 | 2011-11-29 | 가니메드 파마슈티칼스 아게 | 암의 진단 및 치료를 위한 방법 및 조성물 |
EP2221063A1 (en) | 2009-02-20 | 2010-08-25 | Ganymed Pharmaceuticals AG | Methods and compositions for diagnosis and treatment of cancer |
US9487584B2 (en) | 2009-11-11 | 2016-11-08 | Ganymed Pharmaceuticals Ag | Antibodies specific for claudin 6 (CLDN6) |
EP2322555A1 (en) | 2009-11-11 | 2011-05-18 | Ganymed Pharmaceuticals AG | Antibodies specific for claudin 6 (CLDN6) |
WO2011105551A1 (ja) | 2010-02-26 | 2011-09-01 | 国立大学法人大阪大学 | 癌幹細胞の検出方法、及び癌の治療剤または再発予防剤 |
EP2404936A1 (en) | 2010-07-06 | 2012-01-11 | Ganymed Pharmaceuticals AG | Cancer therapy using CLDN6 target-directed antibodies in vivo |
EP3421496A1 (en) | 2011-05-13 | 2019-01-02 | Ganymed Pharmaceuticals GmbH | Antibodies for treatment of cancer expressing claudin 6 |
WO2013035824A1 (ja) | 2011-09-07 | 2013-03-14 | ファーマロジカルズ・リサーチ プライベート リミテッド | 癌幹細胞の分離 |
EP2605017A1 (de) | 2011-12-16 | 2013-06-19 | Protagen AG | Markersequenzen für gynäkologisches Malignom und deren Verwendung |
JP6448056B2 (ja) | 2012-07-19 | 2019-01-09 | アムジェン インコーポレイテッド | ヒトbtnl3タンパク質、核酸、および抗体、ならびにそれらの使用 |
WO2015014376A1 (en) | 2013-07-31 | 2015-02-05 | Biontech Ag | Diagnosis and therapy of cancer involving cancer stem cells |
-
2012
- 2012-04-20 EP EP18179328.2A patent/EP3421496A1/en active Pending
- 2012-04-20 NZ NZ741567A patent/NZ741567A/en unknown
- 2012-04-20 UA UAA201314474A patent/UA115969C2/uk unknown
- 2012-04-20 PL PL15201110T patent/PL3026064T3/pl unknown
- 2012-04-20 RS RS20160121A patent/RS54627B1/en unknown
- 2012-04-20 SI SI201230482T patent/SI2707390T1/sl unknown
- 2012-04-20 WO PCT/EP2012/001721 patent/WO2012156018A1/en active Application Filing
- 2012-04-20 BR BR112013029212A patent/BR112013029212B1/pt active IP Right Grant
- 2012-04-20 NZ NZ706004A patent/NZ706004A/en unknown
- 2012-04-20 MX MX2013013053A patent/MX341147B/es active IP Right Grant
- 2012-04-20 CN CN201710009470.8A patent/CN107011440B/zh active Active
- 2012-04-20 KR KR1020137030171A patent/KR102072183B1/ko active IP Right Grant
- 2012-04-20 JP JP2014510679A patent/JP6276176B2/ja active Active
- 2012-04-20 UA UAA201708784A patent/UA127584C2/uk unknown
- 2012-04-20 PL PL12715856T patent/PL2707390T3/pl unknown
- 2012-04-20 DK DK15201110.2T patent/DK3026064T3/en active
- 2012-04-20 KR KR1020207018103A patent/KR102430870B1/ko active IP Right Grant
- 2012-04-20 SI SI201231496T patent/SI3026064T1/sl unknown
- 2012-04-20 NZ NZ724296A patent/NZ724296A/en not_active IP Right Cessation
- 2012-04-20 CN CN201710009512.8A patent/CN107090043B/zh active Active
- 2012-04-20 SG SG2013070701A patent/SG193551A1/en unknown
- 2012-04-20 KR KR1020227026991A patent/KR20220116069A/ko active IP Right Grant
- 2012-04-20 RU RU2013155455A patent/RU2676731C2/ru active
- 2012-04-20 LT LTEP15201110.2T patent/LT3026064T/lt unknown
- 2012-04-20 DK DK12715856.6T patent/DK2707390T3/en active
- 2012-04-20 HU HUE12715856A patent/HUE028603T2/en unknown
- 2012-04-20 EP EP15201110.2A patent/EP3026064B1/en active Active
- 2012-04-20 ME MEP-2016-39A patent/ME02369B/me unknown
- 2012-04-20 RS RS20181513A patent/RS58087B1/sr unknown
- 2012-04-20 US US14/117,118 patent/US9321842B2/en active Active
- 2012-04-20 CN CN201280022739.1A patent/CN103748112B/zh active Active
- 2012-04-20 AU AU2012258087A patent/AU2012258087B2/en active Active
- 2012-04-20 CA CA2832174A patent/CA2832174C/en active Active
- 2012-04-20 ES ES12715856.6T patent/ES2565063T3/es active Active
- 2012-04-20 EP EP12715856.6A patent/EP2707390B1/en active Active
- 2012-05-08 AR ARP120101613A patent/AR086306A1/es active IP Right Grant
-
2013
- 2013-09-20 ZA ZA2013/07102A patent/ZA201307102B/en unknown
- 2013-10-06 IL IL228738A patent/IL228738B/en active IP Right Grant
- 2013-11-08 MX MX2020001224A patent/MX2020001224A/es unknown
- 2013-11-08 MX MX2020011779A patent/MX2020011779A/es unknown
- 2013-11-08 MX MX2020011778A patent/MX2020011778A/es unknown
-
2014
- 2014-08-22 HK HK14108609.0A patent/HK1195320A1/xx unknown
-
2016
- 2016-02-29 HR HRP20160212TT patent/HRP20160212T1/hr unknown
- 2016-03-01 CY CY20161100181T patent/CY1118608T1/el unknown
- 2016-03-04 SM SM201600064T patent/SMT201600064B/xx unknown
- 2016-03-21 US US15/076,536 patent/US10233253B2/en active Active
-
2017
- 2017-07-07 AU AU2017204663A patent/AU2017204663B2/en active Active
-
2018
- 2018-01-11 JP JP2018002528A patent/JP6637083B2/ja active Active
- 2018-07-05 US US16/028,210 patent/US10919974B2/en active Active
- 2018-12-21 CY CY181101393T patent/CY1121085T1/el unknown
-
2019
- 2019-01-03 HR HRP20190014TT patent/HRP20190014T1/hr unknown
- 2019-08-22 AU AU2019219797A patent/AU2019219797B2/en active Active
-
2020
- 2020-12-30 US US17/138,403 patent/US11859008B2/en active Active
-
2021
- 2021-06-28 AR ARP210101787A patent/AR122771A2/es unknown
- 2021-12-03 AU AU2021277764A patent/AU2021277764A1/en active Pending
-
2023
- 2023-04-12 JP JP2023064843A patent/JP2023089133A/ja active Pending
- 2023-11-27 US US18/520,264 patent/US20240101703A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1121085T1 (el) | Αντισωματα για θεραπευτικη αγωγη καρκινου που εκφραζει κλαυδινη 6 | |
CY1123192T1 (el) | Αντισωματα ειδικα στην κλαουδινη 6 (cldν6) | |
JOP20200192A1 (ar) | أجسام مضادة لـ tigit | |
CY1122456T1 (el) | Μονοκλωνικα αντισωματα εναντιον παραγοντα 15 αυξησης και διαφοροποιησης (gdf-15), και χρησεις αυτων για θεραπευτικη αγωγη καρκινικης καχεξιας και καρκινου | |
EA201691594A1 (ru) | Циклопропиламины в качестве ингибиторов lsd1 | |
MX2017004715A (es) | Anticuerpos anti-ox40 humanizados y usos de los mismos. | |
EA202092609A1 (ru) | Антитела к cd38 для лечения острого миелолейкоза | |
MX2021014286A (es) | Proteinas multiespecificas. | |
TW201613643A (en) | Anti-CDH6 antibody drug conjugates | |
MX361259B (es) | Uso de un fragmento de peptido hmgb1 para el tratamiento del infarto al miocardio. | |
TR201900071T4 (tr) | Kontrollü Over Stimülasyonuna Yönelik Bileşim | |
MX363205B (es) | Ruta sintetica para obtener 2'-deoxi-2',2'-difluorotetrahidrouridi nas. | |
NZ720106A (en) | A process for the preparation of regadenoson | |
EA201692482A1 (ru) | Способы лечения заболеваний антителами, которые связывают рецептор колониестимулирующего фактора 1 (csf1r) | |
EA201990370A1 (ru) | Терапия рака, связанная с crebbp | |
MX2020000636A (es) | Proteinas sinteticas y usos terapeuticos de las mismas. | |
TR201905218T4 (tr) | Nörodejenerati̇f hastaliklarin tedavi̇si̇ i̇çi̇n yararli vi̇tanoli̇dler. | |
EA201690263A1 (ru) | Улучшенные способы получения перампанеля | |
MX2015014470A (es) | Analogos de combretastatina. | |
MX2021007141A (es) | Sintesis de gamma-carbolinas fusionadas con heterociclo sustituido. | |
TW201612192A (en) | Therapy for GIST | |
MX2021007143A (es) | Sintesis de gamma-carbolinas fusionadas con heterociclo sustituido. | |
TR201821021T4 (tr) | Kanser tedavi̇si̇ne yöneli̇k claudin 6 ekspresyonlu anti̇korlar. | |
EA201992022A1 (ru) | Терапевтическая рнк | |
EA201691620A1 (ru) | Циклопропиламины в качестве ингибиторов lsd1 |